The chief of staff of Hungary's Prime Minster, Gergely Gulyas, said on 14 January 2021 that Hungary has reached a deal with China National Pharmaceutical Group Corp ( Sinopharm) to buy COVID-19 vaccines developed by the company, Reuters news agency reported on Thursday.
According to Gulyas, vaccine shipments under the European Union's programme were arriving to Hungary way too slow.
Gulyas was also quoted as telling a government briefing that the second wave of the COVID-19 pandemic has peaked in Hungary and new infections have dropped but restrictions cannot be eased yet.
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Elaris FlexCo signs global licence agreement with Valneva
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
European Commission approves GSK's Arexvy for adults aged 18 and over